180 Life Sciences Engages Kinexum for Help in Making use of for Advertising and marketing Authorisation in the UK
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Firm”), immediately introduced that the Firm has engaged Kinexum, a strategic advisory agency, to assist the Firm in submitting a Advertising and marketing Authorisation Utility (MAA) for adalimumab to deal with progressive early-stage Dupuytren’s illness. […]
Continue Reading